The role of bronchoalveolar hemostasis in the pathogenesis of acute lung injury

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 5, 2008, Pages 475-484

  Hofstra, Jorrit Jan H ^a,b,e   Haitsma, Jack J ^d   Juffermans, Nicole P ^a,b   Levi, Marcel ^a   Schultz, Marcus J ^a,b,c  

^a Department of Intensive Care Medicine ^*  (Netherlands)

^b Laboratory of Experimental Intensive Care and Anesthesiology   (Netherlands)

^c HERMES Critical Care Group   (Netherlands)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Acute lung injury; Acute respiratory distress syndrome; Coagulation; Fibrinolysis

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; BLOOD CLOTTING FACTOR 7A; DROTRECOGIN; FIBRIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTEINASE; THROMBIN; THROMBOPLASTIN; THROMBOXANE A2; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ARTIFICIAL VENTILATION; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFECT; FIBRIN DEPOSITION; FIBRINOLYSIS; HEMOSTASIS; HUMAN; LUNG INFECTION; LUNG INJURY; LUNG LAVAGE; NONHUMAN; PATHOGENESIS; PNEUMONIA; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SEPSIS; VENTILATOR;

ACUTE LUNG INJURY; BRONCHI; CYTOKINES; FIBRIN; FIBRINOLYSIS; HEMOSTASIS; HUMANS; PLASMINOGEN ACTIVATORS; PULMONARY ALVEOLI; RECEPTORS, THROMBIN; RESPIRATORY DISTRESS SYNDROME, ADULT; THROMBIN;

EID: 55049102986     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0028-1092878     Document Type: Review

References (125)

1. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149:818-824
2. Davis KA. Ventilator-associated pneumonia: a review. J Intensive Care Med 2006;21:211-226
3. Dos Santos CC, Slutsky AS. Invited review: mechanisms of ventilator-induced lung injury: a perspective. J Appl Physiol 2000;89:1645-1655
4. Levi M, Ten CH. Disseminated intravascular coagulation. N Engl J Med 1999;341:586-592
5. Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia - a review. Crit Care Med 2006;34:871-877
6. Dahlem P, Bos AP, Haitsma JJ, Schultz MJ, Meijers JC, Lachmann B. Alveolar fibrinolytic capacity suppressed by injurious mechanical ventilation. Intensive Care Med 2005;31:724-732
7. Dahlem P, Bos AP, Haitsma JJ, et al. Mechanical ventilation affects alveolar fibrinolysis in LPS-induced lung injury. Eur Respir J 2006;28:992-998
8. Welty-Wolf KE, Carraway MS, Ortel TL, Piantadosi CA. Coagulation and inflammation in acute lung injury. Thromb Haemost 2002;88:17-25
9. Biemond BJ, Levi M, Ten CH, et al. Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa. Thromb Haemost 1995;73:223-230
10. Levi M, Ten CH, Bauer KA, et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994;93:114-120
11. Levi M, Schultz MJ, Rijneveld AW, van der PT. Bronchoalveolar coagulation and fibrinolysis in endotoxemia and pneumonia. Crit Care Med 2003;31:S238-S242
12. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992;101:816-823
13. Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001;345:408-416
14. Moore KL, Esmon CT, Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 1989;73:159-165
15. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986;163:740-745
16. Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 1991;88:1346-1353
17. Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001;29:2081-2089
18. Eisele B, Lamy M, Thijs LG, et al. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998;24:663-672
19. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286:1869-1878
20. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003;290:238-247
21. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709
22. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004;30:536-555
23. Gunther A, Mosavi P, Heinemann S, et al. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000;161:454-462
24. Idell S, Gonzalez K, Bradford H, et al. Procoagulant activity in bronchoalveolar lavage in the adult respiratory distress syndrome. Contribution of tissue factor associated with factor VII. Am Rev Respir Dis 1987;136:1466-1474
25. Idell S, Koenig KB, Fair DS, Martin TR, McLarty J, Maunder RJ. Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. Am J Physiol 1991;261:L240-L248
26. Fuchs-Buder T, de Moerloose P, Ricou B, et al. Time course of procoagulant activity and D dimer in bronchoalveolar fluid of patients at risk for or with acute respiratory distress syndrome. Am J Respir Crit Care Med 1996;153:163-167
27. Miller DL, Welty-Wolf K, Carraway MS, et al. Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am J Respir Cell Mol Biol 2002;26:650-658
28. Ware LB, Fang X, Matthay MA. Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003;285:L514-L521
29. Okajima K. Antithrombin prevents endotoxin-induced pulmonary vascular injury by inhibiting leukocyte activation. Blood Coagul Fibrinolysis 1998;9(Suppl 2):S25-S37
30. de Moerlosse P, De Benedetti E, Nicod L, Vifian C, Reber G. Procoagulant activity in bronchoalveolar fluids: no relationship with tissue factor pathway inhibitor activity. Thromb Res 1992;65:507-518
31. Idell S. Endothelium and disordered fibrin turnover in the injured lung: newly recognized pathways. Crit Care Med 2002;30:S274-S280
32. Marshall BC, Sageser DS, Rao NV, Emi M, Hoidal JR. Alveolar epithelial cell plasminogen activator. Characterization and regulation. J Biol Chem 1990;265:8198-8204
33. Prabhakaran P, Ware LB, White KE, Cross MT, Matthay MA, Olman MA. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003;285:L20-L28
34. Wygrecka M, Markart P, Ruppert C, et al. Cellular origin of pro-coagulant and (anti)-fibrinolytic factors in bleomycin-injured lungs. Eur Respir J 2007;29:1105-1114
35. Chapman HA, Stahl M, Allen CL, Yee R, Fair DS. Regulation of the procoagulant activity within the bronchoalveolar compartment of normal human lung. Am Rev Respir Dis 1988;137:1417-1425
36. Levi M, van Der POLL, Ten CH, et al. Differential effects of anti-cytokine treatment on bronchoalveolar hemostasis in endotoxemic chimpanzees. Am J Respir Crit Care Med 1998;158:92-98
37. Chapman HA, Yang XL, Sailor LZ, Sugarbaker DJ. Developmental expression of plasminogen activator inhibitor type 1 by human alveolar macrophages. Possible role in lung injury. J Immunol 1990;145:3398-3405
38. Boutten A, Dehoux MS, Seta N, et al. Compartmentalized IL-8 and elastase release within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 1996;153:336-342
39. Dehoux MS, Boutten A, Ostinelli J, et al. Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 1994;150:710-716
40. Millo JL, Schultz MJ, Williams C, et al. Compartmentalization of cytokines and cytokine inhibitors in ventilator-associated pneumonia. Intensive Care Med 2004;30:68-74
41. Abraham E. Coagulation abnormalities in acute lung injury and sepsis. Am J Respir Cell Mol Biol 2000;22:401-404
42. Schultz MJ, Millo J, Levi M, et al. Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax 2004;59:130-135
43. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989;134:1087-1097
44. Altieri DC. Inflammatory cell participation in coagulation. Semin Cell Biol 1995;6:269-274
45. Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997;9:714-724
46. Eckle I, Seitz R, Egbring R, Kolb G, Havemann K. Protein C degradation in vitro by neutrophil elastase. Biol Chem Hoppe Seyler 1991;372:1007-1013
47. Choi G, Schultz MJ, Levi M, van der PT, Millo JL, Garrard CS. Protein C in pneumonia. Thorax 2005;60:705-706
48. Choi G, Wolthuis EK, Bresser P, et al. Mechanical ventilation with lower tidal volumes and positive endexpiratory pressure prevents alveolar coagulation in patients without lung injury. Anesthesiology 2006;105:689-695
49. van der PT, Levi M, Nick JA, Abraham E. Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med 2005;171:1125-1128
50. Choi G, Hofstra JJ, Roelofs JJ, et al. Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats. Crit Care Med 2007;35:1362-1368
51. Choi G, Hofstra JJ, Roelofs JJ, et al. Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats. Crit Care Med 2008;36:204-210
52. Altemeier WA, Matute-Bello G, Frevert CW, et al. Mechanical ventilation with moderate tidal volumes synergistically increases lung cytokine response to systemic endotoxin. Am J Physiol Lung Cell Mol Physiol 2004;287:L533-L542
53. Belperio JA, Keane MP, Burdick MD, et al. Critical role for CXCR2 and CXCR2 ligands during the pathogenesis of ventilator-induced lung injury. J Clin Invest 2002;110:1703-1716
54. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000;342:1301-1308
55. Ranieri VM, Suter PM, Tortorella C, et al. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA 1999;282:54-61
56. Wolthuis EK, Choi G, Dessing MC, et al. Mechanical ventilation with lower tidal volumes and positive endexpiratory pressure prevents pulmonary inflammation in patients without preexisting lung injury. Anesthesiology 2008;108:46-54
57. Haitsma JJ, Wolthuis EK, Schultz MJ, Levi M, Zhang H, Slutsky AS. Ventilator-induced coagulopathy in experimental Streptococcus pneumoniae pneumonia. Presented at: Annual Meeting of the American Thoracic Society; May 20, 2007; San Francisco, CA
58. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000;407:258-264
59. Levi M, van der PT, Ten CH. Tissue factor in infection and severe inflammation. Semin Thromb Hemost 2006;32:33-39
60. Camerer E, Gjernes E, Wiiger M, Pringle S, Prydz H. Binding of factor VIIa to tissue factor on keratinocytes induces gene expression. J Biol Chem 2000;275:6580-6585
61. Ollivier V, Bentolila S, Chabbat J, Hakim J, de Prost D. Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. Blood 1998;91:2698-2703
62. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005;109:227-241
63. Cunningham MA, Romas P, Hutchinson P, Holdsworth SR, Tipping PG. Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages. Blood 1999;94:3413-3420
64. Johnson K, Choi Y, DeGroot E, Samuels I, Creasey A, Aarden L. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J Immunol 1998;160:5130-5135
65. Johnson K, Aarden L, Choi Y, De GE, Creasey A. The proinflammatory cytokine response to coagulation and endotoxin in whole blood. Blood 1996;87:5051-5060
66. Sower LE, Froelich CJ, Carney DH, Fenton JW, Klimpel GR. Thrombin induces IL-6 production in fibroblasts and epithelial cells. Evidence for the involvement of the seven-transmembrane domain (STD) receptor for alpha-thrombin. J Immunol 1995;155:895-901
67. Huang JS, Ramamurthy SK, Lin X, Le Breton GC. Cell signalling through thromboxane A2 receptors. Cell Signal 2004;16:521-533
68. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002;8:1227-1234
69. Goff CD, Corbin RS, Theiss SD, et al. Postinjury thromboxane receptor blockade ameliorates acute lung injury. Ann Thorac Surg 1997;64:826-829
70. Zarbock A, Singbartl K, Ley K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest 2006;116:3211-3219
71. Pitchford SC, Momi S, Giannini S, et al. Platelet P-selectin is required for pulmonary eosinophil and lymphocyte recruitment in a murine model of allergic inflammation. Blood 2005;105:2074-2081
72. Carvalho-Tavares J, Hickey MJ, Hutchison J, Michaud J, Sutcliffe IT, Kubes P. A role for platelets and endothelial selectins in tumor necrosis factor-alpha-induced leukocyte recruitment in the brain microvasculature. Circ Res 2000;87:1141-1148
73. Drew AF, Liu H, Davidson JM, Daugherty CC, Degen JL. Wound-healing defects in mice lacking fibrinogen. Blood 2001;97:3691-3698
74. Perez RL, Ritzenthaler JD, Roman J. Transcriptional regulation of the interleukin-1beta promoter via fibrinogen engagement of the CD18 integrin receptor. Am J Respir Cell Mol Biol 1999;20:1059-1066
75. Roman J, Ritzenthaler JD, Perez RL, Roser SL. Differential modes of regulation of interleukin-1beta expression by extracellular matrices. Immunology 1999;98:228-237
76. Sitrin RG, Pan PM, Srikanth S, Todd RF III. Fibrinogen activates NF-kappa B transcription factors in mononuclear phagocytes. J Immunol 1998;161:1462-1470
77. Idell S, James KK, Levin EG, et al. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 1989;84:695-705
78. Seeger W, Stohr G, Wolf HR, Neuhof H. Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J Appl Physiol 1985;58:326-338
79. Seeger W, Gunther A, Thede C. Differential sensitivity to fibrinogen inhibition of SP-C- vs. SP-B-based surfactants. Am J Physiol 1992;262:L286-L291
80. Esmon CT. The protein C pathway. Chest 2003;124:26S-32S
81. Yasui H, Gabazza EC, Tamaki S, et al. Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse. Am J Respir Crit Care Med 2001;163:1660-1668
82. Murakami K, Okajima K, Uchiba M, et al. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 1996;87:642-647
83. Murakami K, Okajima K, Uchiba M, et al. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 1997;272:L197-L202
84. Slofstra SH, Groot AP, Maris NA, Reitsma PH, Cate HT, Spek CA. Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment. Br J Pharmacol 2006;149:740-746
85. Kotanidou A, Loutrari H, Papadomichelakis E, et al. Inhaled activated protein C attenuates lung injury induced by aerosolized endotoxin in mice. Vascul Pharmacol 2006;45:134-140
86. Liu KD, Levitt J, Zhuo H, et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med 2008;178:618-623
87. Welty-Wolf KE, Carraway MS, Miller DL, et al. Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am J Respir Crit Care Med 2001;164:1988-1996
88. Welty-Wolf KE, Carraway MS, Ortel TL, et al. Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure. Am J Physiol Lung Cell Mol Physiol 2006;290:L21-L31
89. Enkhbaatar P, Okajima K, Uchiba M, Isobe H, Okabe H. Recombinant tissue factor pathway inhibitor prevents lipopolysaccharide-induced systemic hypotension in rats by inhibiting excessive production of nitric oxide. Thromb Haemost 2001;86:1573-1577
90. Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FB Jr, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993;91:2850-2860
91. Carraway MS, Welty-Wolf KE, Miller DL, et al. Blockade of tissue factor: treatment for organ injury in established sepsis. Am J Respir Crit Care Med 2003;167:1200-1209
92. Opal SM, Palardy JE, Parejo NA, Creasey AA. The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis. Crit Care Med 2001;29:13-17
93. Enkhbaatar P, Okajima K, Murakami K, et al. Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation. Am J Respir Crit Care Med 2000;162:1752-1759
94. Horie S, Ishii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res 1990;59:895-904
95. Yamauchi T, Umeda F, Inoguchi T, Nawata H. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem Biophys Res Commun 1989;163:1404-1411
96. Oelschlager C, Romisch J, Staubitz A, et al. Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells. Blood 2002;99:4015-4020
97. Harada N, Okajima K, Kushimoto S, Isobe H, Tanaka K. Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood 1999;93:157-164
98. Kainoh M, Imai R, Umetsu T, Hattori M, Nishio S. Prostacyclin and beraprost sodium as suppressors of activated rat polymorphonuclear leukocytes. Biochem Pharmacol 1990;39:477-484
99. Kaneider NC, Egger P, Dunzendorfer S, Wiedermann CJ. Syndecan-4 as antithrombin receptor of human neutrophils. Biochem Biophys Res Commun 2001;287:42-46
100. Ostrovsky L, Woodman RC, Payne D, Teoh D, Kubes P. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation 1997;96:2302-2310
101. Duensing TD, Wing JS, van Putten JP. Sulfated polysaccharide-directed recruitment of mammalian host proteins: a novel strategy in microbial pathogenesis. Infect Immun 1999;67:4463-4468
102. Kipnis E, Guery BP, Tournoys A, et al. Massive alveolar thrombin activation in Pseudomonas aeruginosa-induced acute lung injury. Shock 2004;21:444-451
103. Hochart H, Jenkins PV, Smith OP, White B. Low-molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-kappaB in LPS-stimulated human monocytes. Br J Haematol 2006;133:62-67
104. Lever R, Page CP. Novel drug development opportunities for heparin. Nat Rev Drug Discov 2002;1:140-148
105. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol 1996;270:L921-L930
106. Schiffer ER, Reber G, de MP, Morel DR. Evaluation of unfractionated heparin and recombinant hirudin on survival in a sustained ovine endotoxin shock model. Crit Care Med 2002;30:2689-2699
107. Darien BJ, Fareed J, Centgraf KS, et al. Low molecular weight heparin prevents the pulmonary hemodynamic and pathomorphologic effects of endotoxin in a porcine acute lung injury model. Shock 1998;9:274-281
108. Slofstra SH, van't Veer C, Buurman WA, Reitsma PH, ten Cate H, Spek CA. Low molecular weight heparin attenuates multiple organ failure in a murine model of disseminated intravascular coagulation. Crit Care Med 2005;33:1365-1370
109. Cox CS Jr, Zwischenberger JB, Traber DL, Traber LD, Haque AK, Herndon DN. Heparin improves oxygenation and minimizes barotrauma after severe smoke inhalation in an ovine model. Surg Gynecol Obstet 1993;176:339-349
110. Murakami K, McGuire R, Cox RA, et al. Heparin nebulization attenuates acute lung injury in sepsis following smoke inhalation in sheep. Shock 2002;18:236-241
111. Stringer KA, Lindenfeld J, Repine AJ, Cohen Z, Repine JE. Tissue plasminogen activator (tPA) inhibits human neutrophil superoxide anion production in vitro. Inflammation 1997;21:27-34
112. Abraham E, Gyetko MR, Kuhn K, et al. Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation. J Immunol 2003;170:5644-5651
113. Hardaway RM, Williams CH, Marvasti M, et al. Prevention of adult respiratory distress syndrome with plasminogen activator in pigs. Crit Care Med 1990;18:1413-1418
114. Stringer KA, Hybertson BM, Cho OJ, Cohen Z, Repine JE. Tissue plasminogen activator (tPA) inhibits interleukin-1 induced acute lung leak. Free Radic Biol Med 1998;25:184-188
115. Choi G, Vlaar AP, Schouten M, et al. Natural anticoagulants limit LPS-induced pulmonary coagulation but not inflammation. Eur Respir J 2007;30:423-428
116. Idell S. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med 2003;31:S213-S220
117. MacLaren R, Stringer KA. Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome. Pharmacotherapy 2007;27:860-873
118. Ware LB, Bastarache JA, Wang L. Coagulation and fibrinolysis in human acute lung injury - new therapeutic targets? Keio J Med 2005;54:142-149
119. Ware LB, Camerer E, Welty-Wolf K, Schultz MJ, Matthay MA. Bench to bedside: targeting coagulation and fibrinolysis in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2006;291:L307-L311
120. Laterre PF, Garber G, Levy H, et al. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 2005;33:952-961
121. Lahteenmaki K, Kuusela P, Korhonen TK. Bacterial plasminogen activators and receptors. FEMS Microbiol Rev 2001;25:531-552
122. Robriquet L, Collet F, Tournoys A, et al. Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response. Respir Res 2006;7:41
123. ISRCTN52566874. Activated protein C versus placebo in the treatment of inflammatory or infectious ALI/ARDS (INFALI): a pathophysiological study on pulmonary microvascular permeability, apoptosis, inflammation and coagulation. 2007
124. Seeger W, Hubel J, Klapettek K, et al. Procoagulant activity in bronchoalveolar lavage of severely traumatized patients-relation to the development of acute respiratory distress. Thromb Res 1991;61:53-64
125. Gunther A, Kalinowski M, Elssner A, Seeger W. Clot-embedded natural surfactant: kinetics of fibrinolysis and surface activity. Am J Physiol 1994;267:L618-L624